Address modern challenges in chronic total occlusion (CTO) interventions with this session focusing on the latest technologies and techniques. Learn key procedural strategies and best practices through detailed case studies, and understand how evolving technology is shaping the future of CTO revascularization.

Gain new insights into patent foramen ovale (PFO) closure with this session exploring age-related outcomes, risk of atrial arrhythmia, and patient selection improvements. Review various imaging approaches for assessing residual shunts and compare guidance techniques including TEE, fluoroscopy, and intracardiac echo from recent clinical registries.

Explore contemporary evidence on left atrial appendage (LAA) closure and associated antithrombotic therapies. This session covers strategies for antithrombotic de-escalation, efficacy and safety in patients with anticoagulation contraindications, breakthrough stroke etiology, and anatomical considerations in high-risk atrial fibrillation patients undergoing ablation.

Discover the diverse clinical scenarios of transcatheter tricuspid valve replacement (TTVR). This session presents complex cases including acute right ventricular afterload mismatch, combined pulmonary and tricuspid valve interventions in carcinoid heart disease, and challenges in dilated cava anatomy, showcasing the expanding frontiers of TTVR therapy.

Paris, France, 19−22 May 2026. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during EuroPCR 2026 and are set to impact practice worldwide. Among them is an individual participant data meta-analysis of 4 randomised controlled trials...

In this review, Henryk Dreger explores the complex interplay between aortic stenosis and coronary artery disease, highlighting the latest evidence on PCI timing and its implications for clinical decision-making.

Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.